巴拿马皮下曲妥珠单抗和静脉注射帕妥珠单抗作为局部HER2+乳腺癌症新辅助治疗的真实世界数据

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2021-05-07 DOI:10.2217/BMT-2021-0003

Franklin Castillero Rodriguez, O. Castillo-Fernandez, Maria Lim-Law, Cristiane Martin Palacios, L. Montano, Stephani Benitez, Jaime Samudio

{"title":"巴拿马皮下曲妥珠单抗和静脉注射帕妥珠单抗作为局部HER2+乳腺癌症新辅助治疗的真实世界数据","authors":"Franklin Castillero Rodriguez, O. Castillo-Fernandez, Maria Lim-Law, Cristiane Martin Palacios, L. Montano, Stephani Benitez, Jaime Samudio","doi":"10.2217/BMT-2021-0003","DOIUrl":null,"url":null,"abstract":"The aim of this study is to determine the effectiveness of subcutaneous trastuzumab in combination with intravenous pertuzumab and chemotherapy for patients with HER2-overexpressing localized breast cancer treated in our center. Methods: This was a descriptive, retrospective, real-world study. Results: Of 156 patients, pathological complete response (pCR) was achieved in 64.1%. A multivariate analysis showed a relationship with a negative hormone receptor (HR) expression and a HER2 score of 3+ by immunohistochemistry. Relapse-free survival (RFS) was higher in patients with pCR. Conclusion: Neoadjuvant therapy with dual blockade using intravenous pertuzumab and subcutaneous trastuzumab for HER2+ localized breast cancer in routine clinical practice resulted in a 64.1% pCR rate. Additionally, this outcome was related to a negative HR expression and HER2 overexpression, and correlated with higher relapse-free survival.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":"1 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2021-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Real-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2+ breast cancer in Panama\",\"authors\":\"Franklin Castillero Rodriguez, O. Castillo-Fernandez, Maria Lim-Law, Cristiane Martin Palacios, L. Montano, Stephani Benitez, Jaime Samudio\",\"doi\":\"10.2217/BMT-2021-0003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim of this study is to determine the effectiveness of subcutaneous trastuzumab in combination with intravenous pertuzumab and chemotherapy for patients with HER2-overexpressing localized breast cancer treated in our center. Methods: This was a descriptive, retrospective, real-world study. Results: Of 156 patients, pathological complete response (pCR) was achieved in 64.1%. A multivariate analysis showed a relationship with a negative hormone receptor (HR) expression and a HER2 score of 3+ by immunohistochemistry. Relapse-free survival (RFS) was higher in patients with pCR. Conclusion: Neoadjuvant therapy with dual blockade using intravenous pertuzumab and subcutaneous trastuzumab for HER2+ localized breast cancer in routine clinical practice resulted in a 64.1% pCR rate. Additionally, this outcome was related to a negative HR expression and HER2 overexpression, and correlated with higher relapse-free survival.\",\"PeriodicalId\":43086,\"journal\":{\"name\":\"Breast Cancer Management\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2021-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/BMT-2021-0003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/BMT-2021-0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

摘要

本研究的目的是确定皮下曲妥珠单抗联合静脉注射帕妥珠单抗和化疗对我们中心治疗的HER2过度表达局部乳腺癌症患者的有效性。方法：这是一项描述性的、回顾性的、真实世界的研究。结果：156例患者中，病理完全反应（pCR）达到64.1%。多变量分析显示，阴性激素受体（HR）表达与HER2免疫组织化学评分为3+有关。pCR患者的无复发生存率（RFS）较高。结论：在常规临床实践中，静脉注射帕妥珠单抗和皮下注射曲妥珠单抗治疗HER2+局限性癌症的双阻断新辅助治疗的pCR率为64.1%。此外，这一结果与HR阴性表达和HER2过度表达有关，并与较高的无复发生存率相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Real-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2+ breast cancer in Panama

The aim of this study is to determine the effectiveness of subcutaneous trastuzumab in combination with intravenous pertuzumab and chemotherapy for patients with HER2-overexpressing localized breast cancer treated in our center. Methods: This was a descriptive, retrospective, real-world study. Results: Of 156 patients, pathological complete response (pCR) was achieved in 64.1%. A multivariate analysis showed a relationship with a negative hormone receptor (HR) expression and a HER2 score of 3+ by immunohistochemistry. Relapse-free survival (RFS) was higher in patients with pCR. Conclusion: Neoadjuvant therapy with dual blockade using intravenous pertuzumab and subcutaneous trastuzumab for HER2+ localized breast cancer in routine clinical practice resulted in a 64.1% pCR rate. Additionally, this outcome was related to a negative HR expression and HER2 overexpression, and correlated with higher relapse-free survival.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.